206 related articles for article (PubMed ID: 23607889)
21. Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.
Veltri L; Cumpston A; Shillingburg A; Wen S; Luo J; Leadmon S; Watkins K; Craig M; Hamadani M; Kanate AS
Cytotherapy; 2015 Dec; 17(12):1785-92. PubMed ID: 26475754
[TBL] [Abstract][Full Text] [Related]
22. Autologous Stem Cell Mobilization in the Age of Plerixafor.
Cooper DL; Medoff E; Patel N; Baker J; Pratt K; Foss F; Seropian SE; Perreault S; Wu Y
Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):411-6. PubMed ID: 27245311
[TBL] [Abstract][Full Text] [Related]
23. The efficacy of residual plerixafor for second-day stem cell mobilization in multiple myeloma patients.
He D; Zhu C; Guo X; Huang X; Han X; Zheng G; Zhao Y; Yang Y; Wu W; Ge J; Zhang E; He J; Cai Z
Transfus Apher Sci; 2023 Jun; 62(3):103618. PubMed ID: 36481258
[TBL] [Abstract][Full Text] [Related]
24. Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization.
Smith VR; Popat U; Ciurea S; Nieto Y; Anderlini P; Rondon G; Alousi A; Qazilbash M; Kebriaei P; Khouri I; de Lima M; Champlin R; Hosing C
Am J Hematol; 2013 Sep; 88(9):754-7. PubMed ID: 23749720
[TBL] [Abstract][Full Text] [Related]
25. Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.
Chhabra S; Callander N; Watts NL; Costa LJ; Thapa B; Kaufman JL; Laubach J; Sborov DW; Reeves B; Rodriguez C; Chari A; Silbermann R; Anderson LD; Bal S; Dhakal B; Nathwani N; Shah N; Medvedova E; Bumma N; Holstein SA; Costello C; Jakubowiak A; Wildes TM; Schmidt T; Orlowski RZ; Shain KH; Cowan AJ; Dholaria B; Cornell RF; Jerkins JH; Pei H; Cortoos A; Patel S; Lin TS; Usmani SZ; Richardson PG; Voorhees PM
Transplant Cell Ther; 2023 Mar; 29(3):174.e1-174.e10. PubMed ID: 36494017
[TBL] [Abstract][Full Text] [Related]
26. Stem Cell Mobilization for Multiple Myeloma Patients Receiving Daratumumab-Based Induction Therapy: A Real- World Experience.
Thurlapati A; Roubal K; Davis JA; Shah SZ; Smith D; McGann M; Gaffney K; Cendagorta A; Maldonado A; Weeda E; Hashmi H
Transplant Cell Ther; 2023 May; 29(5):340.e1-340.e4. PubMed ID: 36804934
[TBL] [Abstract][Full Text] [Related]
27. Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs.
Milone G; Martino M; Spadaro A; Leotta S; Di Marco A; Scalzulli P; Cupri A; Di Martina V; Schinocca E; Spina E; Tripepi G
Br J Haematol; 2014 Jan; 164(1):113-23. PubMed ID: 24138497
[TBL] [Abstract][Full Text] [Related]
28. Reduced-dose plerixafor as a mobilization strategy in autologous hematopoietic cell transplantation: a proof of concept study.
Gutiérrez-Aguirre CH; Alvarado-Navarro DM; Palomares-Leal A; Mejía-Jaramillo G; Salazar-Riojas R; León AG; Colunga-Pedraza PR; Sotomayor-Duque G; Jaime-Pérez JC; Cantú-Rodríguez OG; Del Carmen Tarín-Arzaga L; Flores-Jiménez JA; Gómez-Almaguer D
Transfusion; 2019 Dec; 59(12):3721-3726. PubMed ID: 31618456
[TBL] [Abstract][Full Text] [Related]
29. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data.
Duarte RF; Shaw BE; Marín P; Kottaridis P; Ortiz M; Morante C; Delgado J; Gayoso J; Goterriz R; Martínez-Chamorro C; Mateos-Mazón JJ; Ramírez C; de la Rubia J; Achtereekte H; Gandhi PJ; Douglas KW; Russell NH
Bone Marrow Transplant; 2011 Jan; 46(1):52-8. PubMed ID: 20305700
[TBL] [Abstract][Full Text] [Related]
30. Plerixafor is safe and efficacious for mobilization of peripheral blood stem cells in pediatric patients.
Teusink A; Pinkard S; Davies S; Mueller M; Jodele S
Transfusion; 2016 Jun; 56(6):1402-5. PubMed ID: 27079854
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of Dutch guideline for just-in-time addition of plerixafor to stem cell mobilization in patients who fail with granulocyte-colony-stimulating factor.
Bilgin YM; Visser O; Beckers EA; te Boome LC; Huisman C; Ypma PF; Croockewit AJ; Netelenbos T; Kramer EP; de Greef GE
Transfusion; 2015 May; 55(5):1021-7. PubMed ID: 25641128
[TBL] [Abstract][Full Text] [Related]
32. Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma.
Attolico I; Pavone V; Ostuni A; Rossini B; Musso M; Crescimanno A; Martino M; Iacopino P; Milone G; Tedeschi P; Coluzzi S; Nuccorini R; Pascale S; Di Nardo E; Olivieri A
Biol Blood Marrow Transplant; 2012 Feb; 18(2):241-9. PubMed ID: 21791194
[TBL] [Abstract][Full Text] [Related]
33. Low baseline platelet count predicts poor response to plerixafor in patients with multiple myeloma undergoing autologous stem cell mobilization.
Bakeer M; Zubair AC; Roy V
Cytotherapy; 2020 Jan; 22(1):16-20. PubMed ID: 31879152
[TBL] [Abstract][Full Text] [Related]
34. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
Steinberg M; Silva M
Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
[TBL] [Abstract][Full Text] [Related]
35. Late afternoon dosing of plerixafor for stem cell mobilization: a practical solution.
Cooper DL; Pratt K; Baker J; Medoff E; Conkling-Walsh A; Foss F; Snyder E; Yen W; Seropian SE
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):267-72. PubMed ID: 21658654
[TBL] [Abstract][Full Text] [Related]
36. Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients.
Fruehauf S; Ehninger G; Hübel K; Topaly J; Goldschmidt H; Ho AD; Müller S; Moos M; Badel K; Calandra G
Bone Marrow Transplant; 2010 Feb; 45(2):269-75. PubMed ID: 19597422
[TBL] [Abstract][Full Text] [Related]
37. Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.
Malard F; Kröger N; Gabriel IH; Hübel K; Apperley JF; Basak GW; Douglas KW; Geraldes C; Jaksic O; Koristek Z; Lanza F; Lemoli R; Mikala G; Selleslag D; Worel N; Mohty M; Duarte RF
Biol Blood Marrow Transplant; 2012 Feb; 18(2):314-7. PubMed ID: 22001752
[TBL] [Abstract][Full Text] [Related]
38. [Comparison of Plerixafor or Cyclophosphamide Combined with G-CSF in Mobilization of Peripheral Blood Stem Cells in Multiple Myeloma].
Li WT; Ma LM; Lian Y; Wang QG; Gao ZJ; Zhao S
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1403-1409. PubMed ID: 37846691
[TBL] [Abstract][Full Text] [Related]
39. Addition of plerixafor in poorly mobilized allogeneic stem cell donors.
Zhuang L; Lauro D; Wang S; Yuan S
J Clin Apher; 2022 Aug; 37(4):388-394. PubMed ID: 35633513
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization.
Micallef IN; Sinha S; Gastineau DA; Wolf R; Inwards DJ; Gertz MA; Hayman SR; Hogan WJ; Johnston PB; Lacy MQ; Ansell SM; Buadi F; Dingli D; Dispenzieri A; Litzow MR; Porrata LF; Winters JL; Kumar S
Biol Blood Marrow Transplant; 2013 Jan; 19(1):87-93. PubMed ID: 22922211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
